2022
International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn
Lieberman L, Lopriore E, Baker JM, Bercovitz RS, Christensen RD, Crighton G, Delaney M, Goel R, Hendrickson JE, Keir A, Landry D, La Rocca U, Lemyre B, Maier RF, Muniz‐Diaz E, Nahirniak S, New HV, Pavenski K, dos Santos M, Ramsey G, Shehata N, Guidelines F. International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn. British Journal Of Haematology 2022, 198: 183-195. PMID: 35415922, PMCID: PMC9324942, DOI: 10.1111/bjh.18170.Peer-Reviewed Original ResearchConceptsRole of IVIGIntravenous immunoglobulinExchange transfusionHaemolytic diseaseSafety of IVIGRed blood cell transfusionBlood cell transfusionDuration of hospitalizationSeverity of anemiaEvidence-based recommendationsHigh-quality studiesCell transfusionPrompt treatmentBilirubin levelsSignificant morbidityAlternative therapiesIntensive phototherapyNeurocognitive outcomesManagement of RhInternational guidelinesTransfusionNewbornsDiseasePhototherapyInternational panel
2017
Interleukin-6 receptor α signaling on CD4+ T cells drives RBC alloantibody generation and T follicular helper cell differentiation in a murine model of RBC alloimmunization.
Arneja A, Salazar J, Jiang W, Hendrickson J, Zimring J, Luckey C. Interleukin-6 receptor α signaling on CD4+ T cells drives RBC alloantibody generation and T follicular helper cell differentiation in a murine model of RBC alloimmunization. The Journal Of Immunology 2017, 198: 201.27-201.27. DOI: 10.4049/jimmunol.198.supp.201.27.Peer-Reviewed Original ResearchRBC alloimmunizationRed blood cellsIL-6RαT cellsAntigen-negative red blood cellsFollicular helper cell differentiationInterleukin-6 receptor αFollicular helper cellsHemolytic transfusion reactionsViable therapeutic optionLife-saving therapySignificant clinical problemSignificant clinical consequencesInterleukin-6 receptorHelper cell differentiationSpecific CD4Multiple alloantibodiesOccasional mortalitySignificant morbidityTherapeutic optionsAvailable biologicsFunctional outcomeHelper cellsTransfusion reactionsClinical consequences